These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 35819299)

  • 1. Development, testing, and implementation of a new procedure to assess the clinical added benefit of pharmaceuticals.
    Dóczy V; Wernerné Sódar B; Hölgyesi Á; Merész G; Gaál P
    Int J Technol Assess Health Care; 2022 Jul; 38(1):e58. PubMed ID: 35819299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A critical assessment framework to identify, quantify and interpret the sources of uncertainty in cost-effectiveness analyses.
    Merész G; Dóczy V; Hölgyesi Á; Németh G
    BMC Health Serv Res; 2022 Jun; 22(1):822. PubMed ID: 35752772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health technology assessment of medical devices: What is different? An overview of three European projects.
    Schnell-Inderst P; Mayer J; Lauterberg J; Hunger T; Arvandi M; Conrads-Frank A; Nachtnebel A; Wild C; Siebert U
    Z Evid Fortbild Qual Gesundhwes; 2015; 109(4-5):309-18. PubMed ID: 26354131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug Policy in Hungary.
    Inotai A; Csanádi M; Harsányi A; Németh B
    Value Health Reg Issues; 2017 Sep; 13():16-22. PubMed ID: 29073982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Attempt to increase the transparency of fourth hurdle implementation in Central-Eastern European middle income countries: publication of the critical appraisal methodology.
    Inotai A; Pékli M; Jóna G; Nagy O; Remák E; Kaló Z
    BMC Health Serv Res; 2012 Sep; 12():332. PubMed ID: 22999574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multicriteria decision analysis (MCDA) for health technology assessment: the Queensland Health experience.
    Howard S; Scott IA; Ju H; McQueen L; Scuffham PA
    Aust Health Rev; 2019 Oct; 43(5):591-599. PubMed ID: 30205873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Standardized reporting for rapid relative effectiveness assessments of pharmaceuticals.
    Kleijnen S; Pasternack I; Van de Casteele M; Rossi B; Cangini A; Di Bidino R; Jelenc M; Abrishami P; Autti-Rämö I; Seyfried H; Wildbacher I; Goettsch WG
    Int J Technol Assess Health Care; 2014 Nov; 30(5):488-96. PubMed ID: 25747557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Institute for Clinical and Economic Review - Peterson Health Technology Institute value assessment framework for digital health technologies.
    Pearson SD; Singh P; Beaudoin F; Campbell J; Schapiro L; Emond SK; Pearson C
    J Comp Eff Res; 2023 Dec; 12(12):e230154. PubMed ID: 37965898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modelling approaches for histology-independent cancer drugs to inform NICE appraisals: a systematic review and decision-framework.
    Murphy P; Glynn D; Dias S; Hodgson R; Claxton L; Beresford L; Cooper K; Tappenden P; Ennis K; Grosso A; Wright K; Cantrell A; Stevenson M; Palmer S
    Health Technol Assess; 2021 Dec; 25(76):1-228. PubMed ID: 34990339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Informing a decision framework for when NICE should recommend the use of health technologies only in the context of an appropriately designed programme of evidence development.
    Claxton K; Palmer S; Longworth L; Bojke L; Griffin S; McKenna C; Soares M; Spackman E; Youn J
    Health Technol Assess; 2012; 16(46):1-323. PubMed ID: 23177626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methods for the comparative evaluation of pharmaceuticals.
    Zentner A; Velasco-Garrido M; Busse R
    GMS Health Technol Assess; 2005 Nov; 1():Doc09. PubMed ID: 21289930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Informative value of Patient Reported Outcomes (PRO) in Health Technology Assessment (HTA).
    Brettschneider C; Lühmann D; Raspe H
    GMS Health Technol Assess; 2011 Feb; 7():Doc01. PubMed ID: 21468289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Who does the numbers? The role of third-party technology assessment to inform health systems' decision-making about the funding of health technologies.
    Barbieri M; Hawkins N; Sculpher M
    Value Health; 2009; 12(2):193-201. PubMed ID: 18700865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multicriteria decision analysis in health care decision in oncology: a systematic review.
    Campolina AG; Suzumura EA; Hong QN; de Soárez PC
    Expert Rev Pharmacoecon Outcomes Res; 2022 Apr; 22(3):365-380. PubMed ID: 34913775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Framework for describing and classifying decision-making systems using technology assessment to determine the reimbursement of health technologies (fourth hurdle systems).
    Hutton J; McGrath C; Frybourg JM; Tremblay M; Bramley-Harker E; Henshall C
    Int J Technol Assess Health Care; 2006; 22(1):10-8. PubMed ID: 16673675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Information on new drugs at market entry: retrospective analysis of health technology assessment reports versus regulatory reports, journal publications, and registry reports.
    Köhler M; Haag S; Biester K; Brockhaus AC; McGauran N; Grouven U; Kölsch H; Seay U; Hörn H; Moritz G; Staeck K; Wieseler B
    BMJ; 2015 Feb; 350():h796. PubMed ID: 25722024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identifying and Revealing the Importance of Decision-Making Criteria for Health Technology Assessment: A Retrospective Analysis of Reimbursement Recommendations in Ireland.
    Schmitz S; McCullagh L; Adams R; Barry M; Walsh C
    Pharmacoeconomics; 2016 Sep; 34(9):925-37. PubMed ID: 27034245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncology drugs and added benefit: insights from 3 European health technology assessment agencies on the role of efficacy endpoints.
    Smith N; Fu AC; Fisher T; Meletiche D; Pawar V
    J Med Econ; 2022; 25(1):1-6. PubMed ID: 34809504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.